Investors looking for robust dividend stocks should consider companies with a solid history of profitability and reliable cash flows. These attributes can substantially enhance portfolio returns through consistent dividend income and potential capital appreciation. Among the noteworthy candidates for dividend investments right now are Costco Wholesale and AbbVie.
Costco Wholesale has established itself as a strong performer in the retail sector with a consistent record of increasing its quarterly dividend for more than 20 years. Currently, Costco’s annual dividend stands at $5.20 per share, with a recent quarterly payment of $1.30 made in November 2025. In addition to its regular dividends, Costco has been known to issue special dividends. For example, shareholders received a one-off payment of $15 per share in December 2023, following a $10 special dividend in December 2020.
While the dividend yield of Costco is less than 1%, this is largely attributed to the significant appreciation in its stock price, driven by its strong operational performance. The company places a greater emphasis on reinvesting profits back into the business and issuing large, infrequent special dividends rather than maintaining a high regular payout. Despite a modest regular dividend, Costco delivered a staggering total return of nearly 150% over the past five years, a testament to its effective business model and growth strategy.
Costco’s impressive performance is backed by a low payout ratio of approximately 27%, allowing the company to retain ample earnings for future growth. A significant portion of Costco’s revenues is derived from its membership fees, which exceeded $1.3 billion in the first quarter of fiscal 2026, resulting in a stable cash flow that supports its operational model. This structure enables Costco to operate at thin margins while still providing exceptional value to its members. Loyalty is strong, with renewal rates reaching roughly 92% in the U.S. and Canada.
Furthermore, Costco’s strategy of offering a limited selection of around 4,000 stock-keeping units (SKUs) compared to competitors has strengthened its bargaining power with suppliers. The company’s diverse services, including gas stations and optical centers, contribute additional revenue streams, further insulating Costco from dependency on any single product category. In the fiscal year ending August 31, 2025, Costco reported annual revenue of $275.2 billion, an 8.2% increase from the previous year, along with a net income of $8.1 billion.
On the other hand, AbbVie has also marked its spot as a lucrative dividend stock with a remarkable 54 consecutive years of dividend increases, earning it a reputation as one of the Dividend Kings. The company currently provides a forward annual dividend of $6.92 per share, translating to a yield of approximately 3%, substantially higher than the S&P 500 average yield of 1.1%.
AbbVie has successfully navigated the challenging patent expiration of its former best-seller, Humira, by seeing rapid growth in newer drugs like Skyrizi and Rinvoq. These immunology products are projected to achieve over $31 billion in combined sales by 2027. Following a recent settlement regarding patented litigation for Rinvoq, its U.S. market exclusivity has been extended until 2037, further safeguarding future profits.
The company’s diversification across multiple sectors, including immunology, neuroscience, oncology, and aesthetics, positions it robustly for sustained growth. Recent strategic acquisitions, such as ImmunoGen, have bolstered AbbVie’s portfolio. This acquisition provided access to cutting-edge antibody-drug conjugate (ADC) technologies and added new products like Elahere to its offerings, along with a promising pipeline that is expected to enhance earnings significantly by 2027.
Remarkably, AbbVie’s neuroscience division is now the second-largest segment for the company, which recorded a 20% revenue increase in Q3 2025. Noteworthy growth sources include Vraylar, a treatment for bipolar I disorder and major depressive disorder, along with migraine medications Ubrelvy and Qulipta.
AbbVie also has several promising candidates in its development pipeline, including a novel treatment for Parkinson’s disease, tavapadon, which is currently under FDA review. This new drug is intended to provide effective relief for motor symptoms, specifically addressing gaps in existing therapies.
In the third quarter of 2025, AbbVie reported worldwide net revenues of $15.8 billion, marking a 9.1% year-over-year increase. Over the past 12 months, total revenue reached $59.6 billion. Despite potential volatility in net income due to one-time charges from acquisitions, AbbVie consistently generates high operating income and impressive cash flows, around $19 billion annually as of 2024.
Both Costco and AbbVie represent compelling choices for investors seeking stable dividend-paying stocks that can contribute positively to their overall investment strategies.
